UBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications
It is proposed that UBA1 functions as a proteostasis-innate immunity checkpoint whose biological output is determined by residual enzymatic activity, subcellular distribution, lineage context, and clone size and suggests a mechanism-based approach to therapeutic intervention in VEXAS syndrome and malignancy.